Dr. Maky Zanganeh
Serving as COO since 2020, Dr Maky Zanganeh has been appointed Co-CEO as part of Summit Therapeutics’ plan to assemble a leadership team to guide the group into its next chapter of our growth., Prior to joining the drug discovery and development company, Maky founded Maky Zanganeh and Associates in 2015, and before that held multiple leadership roles at Pharmacyclics, Inc., including COO. In this role, she oversaw all clinical development, regulatory, research, and commercial functions in addition to all business-related matters. She played a key role in the sale of Pharmacyclics to AbbVie Inc. for $21 billion in 2015. Maky is currently a board member of Pulse Biosciences, Inc., and earned the Top Women in Biotech 2013 award and was a finalist for the EY Entrepreneur of the Year award in 2013. She has a Dental Degree of Surgery from the University of Strasbourg and an MBA from Schiller International University in France.
Year appointed: July 2022